Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone Ii

Milani, Amir Eftekhari; Bagheri, Masood; Niyousha, Mohamad Reza; Rezaei, Leila; Hazeri, Somayyeh; Safarpoor, Samad; Abdollahi, Maryam

doi:10.4103/joco.joco_193_21

Cited by 4 publications

(1 citation statement)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was first reported by Capella et al [20], who detected clinically significant LSCD using impression cytology in a 68-year-old man after 7 IVB injections for managing left-eye idiopathic choroidal polypoidal vasculopathy, with a notable improvement 2 months after ipsilateral limbal autograft [20]. However, previous studies have shown no long-term neurodevelopmental defects in preterm infants receiving intravitreal anti-VEGF therapy for retinopathy of prematurity [45,46]. Considering the outcomes of our study, we believe that further evidence is required regarding the long-term effects of anti-VEGF therapy on growth and neurodevelopmental maturation.…”

Section: Discussionsupporting

confidence: 60%

Effects of repeated intravitreal bevacizumab administration on anterior segment parameters and limbal stem cells

Eidizadeh,

Felegary,

Madani

et al. 2023

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Macular edema (ME) is fluid accumulation in the macula caused by vascular leakage. Repeated intravitreal bevacizumab (IVB) injections are extensively used to treat ME of different origins, are well tolerated, and have few side effects. This study evaluated the effects of repeated IVB injections on the anterior segment parameters and limbal stem cells (LSCs) in eyes with ME. Methods: This before–after study involved patients with ME of different causes who underwent repeated IVB injections at the Imam Khomeini Ophthalmology Center in Kermanshah, Iran. Before and after repeated IVB injections, anterior segment parameters were measured using anterior segment optical coherence tomography, and the LSCs were assessed using impression cytology. Results: We enrolled 42 eyes of 42 patients with a mean (standard deviation [SD]) age of 59.6 (7.6) years, of whom 25 (59.5%) were men and 17 (40.5%) were women. The underlying diseases included diabetic ME in 30 eyes (71.4%), central (5 [11.9%]) or branch (3 [7.1%]) retinal vein occlusion, and choroidal neovascularization in 4 eyes (9.5%). The right eye was affected in 22 (52.4%) participants. The mean (SD) number of IVB injections was 4.3 (1.3). After repeated injections, the mean central corneal thickness (CCT) increased, whereas the mean anterior chamber angle (ACA) and anterior chamber depth (ACD) decreased (all P<0.001). Three patients developed LSC deficiency after repeated IVB injections for diabetic ME. Conclusions: We observed a significant increase in the mean CCT and a decrease in the mean ACA and ACD after repeated IVB injections in our series. Three patients developed LSC deficiency after repeated IVB injections for diabetic ME management. The observed effect on LSC may cast doubt on the safety of repeated IVB injections; however, this finding must be verified in multicenter clinical trials with longer follow-up periods and larger study samples.

show abstract

Section: Discussionsupporting

confidence: 60%

Effects of repeated intravitreal bevacizumab administration on anterior segment parameters and limbal stem cells

Eidizadeh,

Felegary,

Madani

et al. 2023

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

show abstract

Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis

Ortiz-Seller,

Martorell,

Barranco

et al. 2024

Survey of Ophthalmology

View full text Add to dashboard Cite

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis

Chen,

Hao,

Zhang

et al. 2023

Ital J Pediatr

View full text Add to dashboard Cite

Background Retinopathy of prematurity (ROP) is typically treated with laser photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF). To the best of our knowledge, most systematic reviews have focused on comparing anti-VEGF against laser treatment while comparisons between different anti-VEGF agents are lacking. Thus, we conducted this meta-analysis to compare the efficacy and safety of different anti-VEGF agents or laser after primary ROP therapy. Methods We conducted a comprehensive search across multiple databases up to November 2022. We included studies that used anti-VEGF or laser for ROP with comparable cohorts. Results Overall, 44 studies were included in this meta-analysis. When comparing anti-VGEF with laser, we found that the anti-VEGF group had a significantly higher retreatment rate (RR = 1.56, 95%CI = [1.06, 2.31], p = 0.03), a longer time from treatment to retreatment (WMD = 5.99 weeks, 95%CI = [4.03, 7.95], p < 0.001), a lower retinal detachment rate (RR = 0.55, 95%CI = [0.30, 0.91], p = 0.02), higher spherical equivalent (WMD = 1.69D, 95%CI = [0.61, 2.77], p = 0.002), lower myopia rate (RR = 0.69, 95%CI = [0.50, 0.97], p = 0.03) and lower anisometropia rate (RR = 0.44, 95%CI = [0.29, 0.67], p = 0.0001). In comparisons between ranibizumab and bevacizumab, the intravitreal ranibizumab (IVR) group was associated with higher recurrence rate (RR = 2.02, 95%CI = [1.49, 2.73], p < 0.0001), higher retreatment rate (RR = 1.70, 95%CI = [1.17, 2.47], p = 0.0006), and lower high myopia rate (RR = 0.31, 95%CI = [0.12, 0.77], p = 0.01). Similarly, when compared to aflibercept and conbercept, the IVR cohort also demonstrated higher recurrence and retreatment rates. While no significant differences were observed in any of the variables included in the statistical analysis in the comparison between bevacizumab and aflibercept. Conclusions Anti-VEGF was associated with higher retreatment and lesser incidence of myopia as compared to laser. Laser therapy was linked to more complications like retinal detachment and myopia. Ranibizumab exhibited higher recurrence and retreatment rates compared to bevacizumab, aflibercept, and conbercept.

show abstract

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone Ii

Cited by 4 publications

References 26 publications

Effects of repeated intravitreal bevacizumab administration on anterior segment parameters and limbal stem cells

Effects of repeated intravitreal bevacizumab administration on anterior segment parameters and limbal stem cells

Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis

Contact Info

Product

Resources

About